BioNTech CEO Ugur Sahin Sells $7.86M in Ordinary Shares Under 10b5-1 Plan

Executive Summary

On September 22, 2026, BioNTech SE (BNTX) filed a Form 4 disclosing that Chief Executive Officer and 10% owner Ugur Sahin sold a total of 79,000 ordinary shares across two consecutive trading sessions on September 21 and September 22, 2026. The gross proceeds from the disposals amounted to approximately $7.86 million.

Transaction Breakdown

• September 21, 2026: Sold 33,000 shares at a weighted average price of $97.8097 per share (~$3.23M).
• September 22, 2026: Sold 46,000 shares at a weighted average price of $100.7182 per share (~$4.63M).
• Combined Total: 79,000 shares at an effective average price of ~$99.50 per share ($7,860,757.30 total value).

Holdings Context

Following these transactions, Dr. Sahin directly holds 410,209 ordinary shares. In addition, he holds an indirect interest in 39,218,111 ordinary shares via Medine GmbH, of which he is the sole shareholder. Relative to his overall direct and indirect stake of nearly 40 million shares, the 79,000 shares sold represent approximately 0.2% of his total beneficial ownership.

Regulatory & Governance Details

All sales reported in this filing were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on June 3, 2026. Given the scheduled nature of the plan and the minimal reduction in Dr. Sahin's overarching beneficial ownership position, this transaction is assessed as having Medium trading significance.